Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Melatonin Prevents the Progression of MASLD via Inhibiting FFAs-Induced Ferroptosis through KEAP1/NRF2/HO-1 Pathway

  • Shuojiao Li (Department of Pharmacy, the First Affiliated Hospital of Anhui Medical University) ;
  • Peng Rao (School of Pharmacy, Anhui Medical University) ;
  • Wenxian Yu (School of Pharmacy, Anhui Medical University) ;
  • Yue Tang (School of Pharmacy, Anhui Medical University) ;
  • Xuanpeng Jiang (School of Pharmacy, Anhui Medical University) ;
  • Jiatao Liu (Department of Pharmacy, the First Affiliated Hospital of Anhui Medical University)
  • Received : 2025.03.07
  • Accepted : 2025.06.26
  • Published : 2025.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

The accumulation of free fatty acids (FFAs) in hepatocytes is a key characteristic of metabolic dysfunction-associated steatotic liver disease (MASLD), which leads to lipid peroxidation and ultimately results in ferroptosis. Currently, there is an absence of efficacious therapeutic options available for the management of MASLD. Consequently, an in-depth exploration of the roles of FFAs and ferroptosis in the progression of MASLD may reveal hitherto unidentified therapeutic targets. In the study, we established an early lesion model of MASLD, namely NAFL, and comprehensive analyses of lipid metabolism, hepatocellular injury, iron homeostasis, and ferroptosis were performed. The HFD and FFAs treatment significantly elevated the expression of enzymes associated with lipid synthesis, including ACC1 and FASN, leading to enhanced lipid accumulation in hepatocytes. Additionally, HFD and FFAs resulted in increased iron loading and a reduction in the levels of the antioxidant enzyme GPX4, which ultimately triggers ferroptosis. In contrast, the administration of melatonin effectively inhibited the activity of lipid synthesis-related enzymes, decreased hepatic lipid deposition, alleviated free fatty acid-induced iron dysregulation, and mitigated liver damage. Mechanistically, melatonin has been shown to attenuate hepatocyte ferroptosis by modulating the KEAP1/NRF2/HO-1 pathway, which in turn diminishes free fatty acids-induced oxidative stress. In conclusion, melatonin alleviates MASLD progression by curbing FFAs-induced oxidative stress and ferroptosis. These findings provide valuable insights into the mechanisms underlying MASLD progression and highlight melatonin as a potential therapeutic agent for the management of MASLD.

Keywords

Acknowledgement

This study was supported by the National Natural and Science Foundation of China (grant no. 82072687) and the Anhui provincial Natural Science Foundation (grant no. 2008085MH257).

References

  1. Ajoolabady, A., Aslkhodapasandhokmabad, H., Libby, P., Tuomeilehto, J., Lip, G. Y. H., Penninger, J. M., Richarrdson, D. R., Tang, D. L., Zhou, H., Wang, S. Y., Kionsky, D. J., Kroemer, G. and Ren, J. (2021) Ferritinophagy and ferroptosis in the management of metabolic diseases. Trends Endocrinol. Metab. 32, 444-462. https://doi.org/10.1016/j.tem.2021.04.010
  2. Anwar, S. D., Foster, C. and Ashraf, A. (2023) Lipid disorders and metabolic-associated fatty liver disease. Endocrinol. Metabol. Clin. North Amer. 52, 445-457. https://doi.org/10.1016/j.ecl.2023.01.003
  3. Bahrami, M., Cheraghpour, M., Jafarirad, S., Alavinejad, P., Asadi, F., Hekmatdoost, A., Mohammadi, M. and Yari, Z. (2020) The effect of melatonin on treatment of patients with non-alcoholic fatty liver disease: a randomized double blind clinical trial. Complement. Ther. Med. 52, 102452.
  4. Bhattacharya, S., Patel, K. K., Dehari, D., Agrawal, A. K. and Singh, S. (2019) Melatonin and its ubiquitous anticancer effects. Mol. Cell. Biochem. 462, 133-155. https://doi.org/10.1007/s11010-019-03617-5
  5. Bocheva, G., Bakalov, D., Iliev, P. and Tafradjiiska-Hadjiolova, R. (2024) The vital role of melatonin and its metabolites in the neuroprotection and retardation of brain aging. Int. J. Mol. Sci. 25, 5122.
  6. Chen, H. T., Han, R. L., Yu, B. B., Zhang, Y. F., Fu, L. H., Lv, B. Q., Tian, Y. Z., Yang, S. J., Hu, Y. T., Hua, J. H., Zuo, Q. Q. and Gong, S. P. (2024) Melatonin alleviates heme-induced ferroptosis via activating the Nrf2/HO-1 pathway in neurons. Eur. Rev. Med. Pharmacol. Sci. 28, 4277-4289.
  7. Chitimus, D. M., Popescu, M. R., Voiculescu, S. E., Panaitescu, A. M., Pavel, B., Zagrean, L. and Zagrean, A. M. (2020) Melatonin's impact on antioxidative and anti-inflammatory reprogramming in homeostasis and disease. Biomolecules 10, 1211.
  8. Fan, X. D., Song, Y. F. and Zhao, J. J. (2024) Evolving liver disease insights from NAFLD to MASLD. Trends Endocrinol. Metab. 35, 683-686. https://doi.org/10.1016/j.tem.2024.02.012
  9. Galano, A. and Reiter, R. J. (2018) Melatonin and its metabolites vs oxidative stress: from individual actions to collective protection. J. Pineal Res. 65, e12514.
  10. Gao, H., Jin, Z. M., Bandyopadhyay, G., Wang, G. W., Zhang, D. H., Rocha, K. C. E., Liu, X., Zhao, H. Y., Kisseleva, T., Brenner, D. A., Karin, M. and Ying, W. (2022) Aberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosis. Cell Metab. 34, 1201-1213. https://doi.org/10.1016/j.cmet.2022.07.006
  11. Guan, Q. Y., Wang, Z. X., Hu, K. Y., Cao, J., Dong, Y. L. and Chen, Y. X. (2023) Melatonin ameliorates hepatic ferroptosis in NAFLD by inhibiting ER stress via the MT2/cAMP/PKA/IRE1 signaling pathway. Int. J. Biol. Sci. 19, 3937-3950. https://doi.org/10.7150/ijbs.85883
  12. He, H., Liao, S. L., Zeng, Y. P., Liang, L. B., Chen, J. and Tao, C. A. (2022) Causal relationships between metabolic-associated fatty liver disease and iron status: two-sample Mendelian randomization. Liver Int. 42, 2759-2768. https://doi.org/10.1111/liv.15455
  13. Heeren, J. and Scheja, L. (2021) Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol. Metab. 50, 101238.
  14. Hsu, L. W. and Chien, Y. W. (2023) Effects of melatonin supplementation on lipid metabolism and body fat accumulation in ovariectomized rats. Nutrients 15, 2800.
  15. Huimin, L., Jie, Y., Fengtao, G., Zhibo, J., Jiahan, X., Chongrui, W., Meihong, L. and Jingsheng, L. (2023) Zeaxanthin prevents ferroptosis by promoting mitochondrial function and inhibiting the p53 pathway in free fatty acid-induced HepG2 cells. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1868, 159287.
  16. Ipsen, D. H., Lykkesfeldt, J. and Tveden-Nyborg, P. (2018) Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell. Mol. Life Sci. 75, 3313-3327. https://doi.org/10.1007/s00018-018-2860-6
  17. Jiang, X. J., Stockwell, B. R. and Conrad, M. (2021) Ferroptosis: mechanisms, biology and role in disease. Nat. Rev. Mol. Cell Biol. 22, 266-282. https://doi.org/10.1038/s41580-020-00324-8
  18. Jin, J. X., Sun, J. T., Jiang, C. Q., Cui, H. D., Bian, Y., Lee, S., Zhang, L., Lee, B. C. and Liu, Z. H. (2022) Melatonin regulates lipid metabolism in porcine cumulus-oocyte complexes via the melatonin receptor 2. Antioxidants 11, 687.
  19. Kim, D., Kim, W. D., Kim, S. K., Moon, D. H. and Lee, S. J. (2020) TGF-β1-mediated repression of SLC7A11 drives vulnerability to GPX4 inhibition in hepatocellular carcinoma cells. Cell Death Dis. 11, 406.
  20. Kimura, I., Ichimura, A., Ohue-Kitano, R. and Igarashi, M. (2020) Free fatty acid receptors in health and disease. Physiol. Rev. 100, 171-210. https://doi.org/10.1152/physrev.00041.2018
  21. Kruemmel, B., von Hanstein, A. S., Ploetz, T., Lenzen, S. and Mehmeti, I. (2022) Differential effects of saturated and unsaturated free fatty acids on ferroptosis in rat β-cells. J. Nutr. Biochem. 106, 109013.
  22. Ku, H., Kim, Y., Kim, A. L., Lee, G., Choi, Y. and Kim, B. (2023) Protective effects of melatonin in high-fat diet-induced hepatic steatosis via decreased intestinal lipid absorption and hepatic cholesterol synthesis. Endocrinol. Metab. 38, 557-567. https://doi.org/10.3803/EnM.2023.1672
  23. Lands, B. (2014) Historical perspectives on the impact of n-3 and n-6 nutrients on health. Prog. Lipid Res. 55, 17-29. https://doi.org/10.1016/j.plipres.2014.04.002
  24. Lee, J. Y., Kim, W. K., Bae, K. H., Lee, S. C. and Lee, E. W. (2021) Lipid metabolism and ferroptosis. Biology (Basel) 10, 184.
  25. Li, Q., Tan, J. X., He, Y., Bai, F., Li, S. W., Hou, Y. W., Ji, L. S., Gao, Y. T., Zhang, X., Zhou, Z. H., Yu, Z., Fang, M., Gao, Y. Q. and Li, M. (2022) Atractylenolide III ameliorates non-alcoholic fatty liver disease by activating hepatic adiponectin receptor 1-mediated AMPK pathway. Int. J. Biol. Sci. 18, 1594-1611. https://doi.org/10.7150/ijbs.68873
  26. Mi, Y., Wei, C. Q., Sun, L. Y., Liu, H. R., Zhang, J. Y., Luo, J. L., Yu, X. H., He, J., Ge, H. Y. and Liu, P. (2023) Melatonin inhibits ferroptosis and delays age-related cataract by regulating SIRT6/p-Nrf2/GPX4 and SIRT6/NCOA4/FTH1 pathways. Biomed. Pharmacother. 157, 114048.
  27. Minich, D. M., Henning, M., Darley, C., Fahoum, M., Schuler, C. B. and Frame, J. (2022) Is melatonin the "Next Vitamin D"?: a review of emerging science, clinical uses, safety, and dietary supplements. Nutrients 14, 3934.
  28. Ou, T. H., Tung, Y. T., Yang, T. H. and Chien, Y. W. (2019) Melatonin improves fatty liver syndrome by inhibiting the lipogenesis pathway in hamsters with high-fat diet-induced hyperlipidemia. Nutrients 11, 748.
  29. Park, J. H., Seo, I., Shim, H. M. and Cho, H. (2020) Melatonin ameliorates SGLT2 inhibitor-induced diabetic ketoacidosis by inhibiting lipolysis and hepatic ketogenesis in type 2 diabetic mice. J. Pineal Res. 68, e12623.
  30. Paul, B., Lewinska, M. and Andersen, J. B. (2022) Lipid alterations in chronic liver disease and liver cancer. JHEP Rep. 4, 100479.
  31. Pope, L. E. and Dixon, S. J. (2023) Regulation of ferroptosis by lipid metabolism. Trends Cell Biol. 33, 1077-1087. https://doi.org/10.1016/j.tcb.2023.05.003
  32. Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., Arrese, M., Bataller, R., Beuers, U., Boursier, J., Bugianesi, E., Byrne, C. D., Narro, G. E. C., Chowdhury, A., Cortez-Pinto, H., Cryer, D. R., Cusi, K., El-Kassas, M., Klein, S., Eskridge, W., Fan, J. G., Gawrieh, S., Guy, C. D., Harrison, S. A., Kim, S. U., Koot, B. G., Korenjak, M., Howdley, K. V., Lacaille, F., Loomba, R., Mitchell-Thain, R., Morgan, T. R., Powell, E. E., Roden, M., Romero-Gómez, M., Silva, M., Singh, S. P., Sookbian, S. C., Spearman, C. W., Tiniakos, D., Valenti, L., Vos, M. B., Wong, V. W. S., Xanthakos, S., Yilmaz, Y., Younossi, Z., Hobbs, A., Villota-Rivas, M. and Newsome, P. N.; NAFLD Nomenclature consensus group (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78, 1966-1986. https://doi.org/10.1097/HEP.0000000000000520
  33. Rochette, L., Dogon, G., Rigal, E., Zeller, M., Cottin, Y. and Vergely, C. (2023) Lipid peroxidation and iron metabolism: two corner stones in the homeostasis control of ferroptosis. Int. J. Mol. Sci. 24, 449.
  34. Rui, T. Y., Wang, H. C., Li, Q. Q., Cheng, Y., Gao, Y., Fang, X. X., Ma, X. Y., Chen, G., Gao, C., Gu, Z. Y., Song, S. C., Zhang, J., Wang, C. L., Wang, Z. F., Wang, T., Zhang, M. Y., Min, J. X., Chen, X. P., Tao, L. Y., Wang, F. D. and Luo, C. L. (2021) Deletion of ferritin H in neurons counteracts the protective effect of melatonin against traumatic brain injury-induced ferroptosis. J. Pineal Res. 70, e12704.
  35. Saha, M., Das, S., Manna, K. and Das Saha, K. (2023) Melatonin targets ferroptosis through bimodal alteration of redox environment and cellular pathways in NAFLD model. Biosci. Rep. 43, BSR20230128.
  36. Shojaie, L., Iorga, A. and Dara, L. (2020) Cell death in liver diseases: a review. Int. J. Mol. Sci. 21, 9682.
  37. Small, L., Lundell, L. S., Iversen, J., Ehrlich, A. M., Dall, M., Basse, A. L., Dalbram, E., Hansen, A. N., Treebak, J. T., Barres, R. and Zierath, J. R. (2023) Seasonal light hours modulate peripheral clocks and energy metabolism in mice. Cell Metab. 35, 1722-1735. https://doi.org/10.1016/j.cmet.2023.08.005
  38. Sun, G. Y., Wang, Y. N., Yang, L., Zhang, Z. H., Zhao, Y. S., Shen, Z. S., Han, X. T., Du, X. A., Jin, H., Li, C. Y., Wang, S. L., Zhang, Z. T. and Zhang, D. (2023) Rebalancing liver-infiltrating CCR3+ and CD206++ monocytes improves diet-induced NAFLD. Cell Rep. 42, 112753.
  39. Sun, Y. P., Wang, J. F., Guo, X. J., Zhu, N. L., Niu, L. L., Ding, X., Xie, Z. S., Chen, X. L. and Yang, F. Q. (2021) Oleic acid and eicosapentaenoic acid reverse palmitic acid-induced insulin resistance in human HepG2 cells via the reactive oxygen species/JUN pathway. GPB 19, 754-771. https://doi.org/10.1016/j.gpb.2019.06.005
  40. Tacke, F., Horn, P., Wong, V. W. S., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., Yki-Järvinen, H., Gastaldelli, A., Vettor, R., Frühbeck, G., Dicker, D., Easl, Easd and Easo (2024) EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 81, 492-542. https://doi.org/10.1016/j.jhep.2024.04.031
  41. Tong, J., Li, D. J., Meng, H. B., Sun, D. Y., Lan, X. T., Ni, M., Ma, J. W., Zeng, F. Y., Sun, S. J., Fu, J. T., Li, G. Q., Ji, Q. X., Zhang, G. Y., Shen, Q. R., Wang, Y. Y., Zhu, J. H., Zhao, Y., Wang, X. J., Liu, Y., Ouyang, S. X., Sheng, C. Q., Shen, F. M. and Wang, P. (2022) Targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver disease. Acta Pharm. Sin. B 12, 3650-3666.
  42. Videla, L. A. and Valenzuela, R. (2022) Perspectives in liver redox imbalance: toxicological and pharmacological aspects underlying iron overloading, nonalcoholic fatty liver disease, and thyroid hormone action. Biofactors 48, 400-415. https://doi.org/10.1002/biof.1797
  43. Wang, S. D., Liu, Z. J., Geng, J. F., Li, L. G. and Feng, X. J. (2022a) An overview of ferroptosis in non-alcoholic fatty liver disease. Biomed. Pharmacother. 153, 113374.
  44. Wang, X. B., Zhang, L. and Dong, B. N. (2024) Molecular mechanisms in MASLD/MASH-related HCC. Hepatology doi: 10.xxxx/xxxx [Online ahead of print]. https://doi.org/10.xxxx/xxxx
  45. Wang, Y., Chen, C. J., Chen, J. J., Sang, T. T., Peng, H., Lin, X. J., Zhao, Q., Chen, S. J., Eling, T. and Wang, X. Y. (2022b) Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation. Redox Biol. 52, 102322.
  46. Wang, Y. J., Guo, W. L., Xu, H. C., Tang, K. Q., Zan, L. N. and Yang, W. C. (2019) Melatonin suppresses milk fat synthesis by inhibiting the mTOR signaling pathway via the MT1 receptor in bovine mammary epithelial cells. J. Pineal Res. 67, e12593.
  47. Wu, Q. B., Chen, Z. H., Ding, Y., Tang, Y. T. and Cheng, Y. W. (2022) Protective effect of traditional Chinese medicine on non-alcoholic fatty liver disease and liver cancer by targeting ferroptosis. Front. Nutr. 9, 1033129.
  48. Xu, D. J., Liu, L. B., Zhao, Y. J., Yang, L., Cheng, J. Y., Hua, R. M., Zhang, Z. L. and Li, Q. W. (2020) Melatonin protects mouse testes from palmitic acid-induced lipotoxicity by attenuating oxidative stress and DNA damage in a SIRT1-dependent manner. J. Pineal Res. 69, e12690.
  49. Zhang, H., Liu, X. Y., Elsabagh, M., Zhang, Y., Ma, Y., Jin, Y. Q., Wang, M. Z., Wang, H. R. and Jiang, H. H. (2022) Effects of the gut microbiota and barrier function on melatonin efficacy in alleviating liver injury. Antioxidants 11, 1727.
  50. Zhang, Q., Kong, X. J., Yuan, H., Guan, H. J., Li, Y. and Niu, Y. C. (2019) Mangiferin improved palmitate-induced-insulin resistance by promoting free fatty acid metabolism in HepG2 and C2C12 cells via PPAR: mangiferin improved insulin resistance. J. Diabetes Res. 2019, 2052675.
  51. Zhao, C. Z., Xiao, C. S., Feng, S. Q. and Bai, J. X. (2023) Artemisitene alters LPS-induced oxidative stress, inflammation and ferroptosis in liver through Nrf2/HO-1 and NF-kB pathway. Front. Pharmacol. 14, 1177542.